UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, Catalysts
Citigroup raised its rating on Acorda Therapeutics (NASDAQ: ACOR ) from Neutral to Buy and raised its price target from $28 to $33. Citigroup said, "We expect Ampyra to continue to grow fueled by modest market share gains and price increases. We project a 10% price increase in Q1:13
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here